A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate

被引:29
|
作者
Wu, Qier [1 ,2 ]
Peters, Sheila Annie [1 ]
机构
[1] Merck KGaA, Quantitat Pharmacol, Darmstadt, Germany
[2] Univ Paris 05, Paris, France
来源
关键词
PREDICTIVE PERFORMANCE; MONTELUKAST; INFANTS; MODEL; PREMATURE; BOSENTAN; CHILDREN; DRUGS; THEOPHYLLINE; CLINDAMYCIN;
D O I
10.1002/psp4.12385
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physiologically-based pharmacokinetic models are increasingly applied for pediatric dose selection along with traditional methods such as allometry and population pharmacokinetic models. We report a retrospective evaluation of the three methods. Pediatric population pharmacokinetic models sourced from literature for a subset of eight compounds were used to predict clearances for children < 2 years when they were within the modeled age range (interpolation, N = 11) or including those outside the modeled age range (interpolation and extrapolation, N = 18). Pediatric/adult clearance ratios were evaluated with a strict performance criterion of 0.8-1.25 and with twofold criteria. For children > 2 years, 58-75% of the clinical studies (N = 10) met the strict criteria, and > 80% of the clinical studies were predicted within twofold by all three methods. For children < 2 years, physiologically-based pharmacokinetic, allometry with age-dependent exponents, and pediatric population pharmacokinetic models predict 54%, 82%, and 64% within twofold of the observed, respectively.
引用
收藏
页码:220 / 229
页数:10
相关论文
共 50 条
  • [31] Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
    Moss, Darren Michael
    Siccardi, Marco
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (17) : 3963 - 3979
  • [32] Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
    Malik, Paul R., V
    Edginton, Andrea N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (11): : 835 - 844
  • [33] Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development
    Glassman, Patrick M.
    Balthasar, Joseph P.
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : 3 - 13
  • [34] Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
    Glassman, Patrick M.
    Balthasar, Joseph P.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (04) : 427 - 446
  • [35] Physiologically-based modeling of methylprednisolone pharmacokinetics across species with extrapolations to humans
    Yu, Ruihong
    Jusko, William J.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 114 (05)
  • [36] Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
    Patrick M. Glassman
    Joseph P. Balthasar
    Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43 : 427 - 446
  • [37] A MECHANISTIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO PREDICT THE PHARMACOKINETICS OF R/S-OXAZEPAM AFTER ORAL DOSING
    Turner, David B.
    Pade, Devendra
    Jamei, Masoud
    Neuhoff, Sibylle
    DRUG METABOLISM REVIEWS, 2015, 47 : 221 - 222
  • [38] MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis
    Huestis, Marilyn A.
    Smith, William B.
    Leonowens, Cathrine
    Blanchard, Rebecca
    Viaccoz, Aurelien
    Spargo, Erin
    Miner, Nicholas B.
    Yazar-Klosinski, Berra
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (02): : 376 - 388
  • [39] EFFECT OF PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS ON PROPRANOLOL PHARMACOKINETICS USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL IN HUMANS
    Kiriyama, Akiko
    Honbo, Akino
    Iga, Katsumi
    DRUG METABOLISM REVIEWS, 2007, 39 : 154 - 154
  • [40] Understanding intra-mammary beta-lactam pharmacokinetics using a physiologically-based model
    Woodward, A.
    Whittem, T.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 : 19 - 19